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Metabolic demand and altered supply of essential nutrients is poorly characterised in patients with advanced cancer. A
possible imbalance or deﬁciency of essential fatty acids is suggested by reported beneﬁcial effects of ﬁsh oil supplementation.
To assess fatty acid status (composition of plasma and neutrophil phospholipids) in advanced cancer patients before and after
14 days of supplementation (12+1 g day
71) with ﬁsh (eicosapentaenoic acid, and docosahexaenoic acid) or placebo (olive)
oil. Blood was drawn from cancer patients experiencing weight loss of 45% body weight (n=23). Fatty acid composition of
plasma phospholipids and the major phospholipid classes of isolated neutrophils were determined using gas liquid
chromatography. At baseline, patients with advanced cancer exhibited low levels (530% of normal values) of plasma
phospholipids and constituent fatty acids and elevated 20:4 n-6 content in neutrophil phospholipids. High n-6/n-3 fatty acid
ratios in neutrophil and plasma phospholipids were inversely related to body mass index. Fish oil supplementation raised
eicosapentaenoic acid and docosahexaenoic acid content in plasma but not neutrophil phospholipids. 20:4 n-6 content was
reduced in neutrophil PI following supplementation with ﬁsh oil. Change in body weight during the supplementation period
related directly to increases in eicosapentaenoic acid in plasma. Advanced cancer patients have alterations in lipid metabolism
potentially due to nutritional status and/or chemotherapy. Potential obstacles in fatty acid utilisation must be addressed in
future trials aiming to improve outcomes using nutritional intervention with ﬁsh oils.
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Dietary supplementation with the n-3 polyunsaturated fatty acids
(PUFA), eicosapentanoic acid (EPA) and docosahexanoic acid
(DHA) as either ﬁsh oil capsules or a ﬁsh oil- supplemented enteral
formula has been reported to attenuate weight loss, increase appe-
tite, improve quality of life and prolong survival in weight losing
cancer patients (Wigmore et al, 1996, 1997, 2000; Barber et al,
1999). Beneﬁcial effects of n-3 fatty acid supplementation imply
the presence of an imbalance between essential n-6 and n-3 fatty
acids or a deﬁciency of n-3 fatty acids. Indices of fatty acid status
may have prognostic value for selecting patients likely to obtain
beneﬁts from supplementation, however, to date supplementation
has not been prospectively examined based on determined fatty
acid status. Detailed indices of fatty acid status are also of interest
for assessing the efﬁcacy of supplementation protocols.
The fatty acid status of patients with advanced cancer is not well
characterised. There is some evidence for abnormalities in lipid
metabolism, including increased lipolysis (Kitada et al, 1982; Taylor
et al, 1992) and oxidation of free fatty acids, (Hansell et al, 1986;
Douglas and Shaw, 1990) and hyper-triglyceridemia (Grunfeld and
Feingold, 1996; Tisdale, 1999). Abnormalities of plasma lipid
proﬁles of cancer patients compared to healthy individuals have
been reported (McClinton et al, 1991). Furthermore, many drug
agents used to treat cancer have been reported to inﬂuence lipid
metabolism (Ara and Teicher, 1996).
Fatty acid composition of plasma phospholipid (PL) and differ-
ent cell types (erythrocytes, neutrophils) reﬂect, respectively, short
and long term patterns of dietary fatty acid consumption, and are
frequently used as indices of fatty acid status (Clandinin et al, 1983;
Stanford et al, 1991; Diboune et al, 1992; Pratt et al, 2001).
Neutrophils are of particular interest as these cells have been impli-
cated in several disease states with an inﬂammatory component
(Sperling et al, 1993; Matzner, 1997; Matsukawa and Yoshinaga,
1998; Ambrosio and Tritto, 1999). Neutrophils secrete and respond
to several cytokines involved in the wasting response of cancer
(Cassatella et al, 1997) which are attenuated by dietary ﬁsh oils
(Blok et al, 1996; Barber et al, 1998). Furthermore, major neutro-
phil functions are membrane dependent (Deitch, 1984; de Pablo
and Alvarez de Cienfuegos, 2000). Therefore, the ability to alter
the membrane composition of neutrophils by ﬁsh oil supplementa-
tion may have important implications for reducing inﬂammation
and wasting in advanced cancer patients.
The objectives of this study were (1) to assess the fatty acid
composition of plasma and neutrophil PL of patients with
advanced cancer and to compare this with other patient groups
and healthy subjects; (2) to assess n-6 and n-3 fatty acid content
and extent of incorporation of supplemented oils into plasma
and neutrophil PL in patients with advanced cancer, and (3) to
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cell PL and some select parameters of nutritional status.
MATERIALS AND METHODS
Materials
H-plates and G-plates were purchased from Analtech (Newark, DE,
USA). All solvents were purchased from VWR (Edmonton, AB,
Canada). Bovine serum albumin (BSA, Fraction V), trypan blue,
Ficoll Hypaque gradients, chemicals for buffers and all other lipid
supplies, including standards, were purchased from Sigma Chemi-
cals (St. Louis, MO, USA).
Subjects
Protocols for study of all subjects were reviewed and approved by
the Research Ethics Board of the Alberta Cancer Board or Faculty
of Medicine Research Ethics Board of the University of Alberta. All
subjects gave informed consent. Due to the paucity of reference
data for fatty acid composition of plasma and immune cells in
advanced cancer patients, multiple subject groups were selected
for comparison. We compared patients with advanced cancer to
victims of major burn injury, which characteristically have a very
strong inﬂammatory reaction and marked changes in phospholi-
pids (Pratt et al, 2001) as well as a group of breast cancer
patients receiving high dose chemotherapy to assess the effect of
chemotherapy on fatty acids. Each group of subjects had plasma
and cellular PL compositions assessed using the same method in
the same laboratory as the advanced cancer group. In the absence
of a large base of reference data, these patient groups, which repre-
sent a wide range of patient groups from critically ill to healthy
subjects, were used to obtain a context for the range of plasma
PL fatty acids observed in advanced cancer patients in this study.
A group of healthy subjects from the local population served as
a control comparison to provide reference values for the healthy
population as an age and sex matched control cohort was not feasi-
ble.
Advanced cancer Patients with advanced cancer (deﬁned as
locally recurrent or metastatic) were recruited from the Acute
Palliative Care Unit and Hospice, Caritas Health Group, and both
hospitalised and outpatients at the Cross Cancer Institute (Edmon-
ton, Alberta, Canada). Inclusion criteria included: (1) presence of
anorexia, deﬁned as 43 on a visual analogue scale; (2) loss of
5% or more of their pre-illness body weight; (3) ability to maintain
oral intake, (4) normal cognition, deﬁned as a normal Mini-Mental
State examination (Periera et al, 1998) for age and level of educa-
tion and (5) ability and willingness to give written, informed
consent. Eligible participants were randomised using a computer-
generated sequence and allocated to receive identical 1 g gelatin
capsules containing ﬁsh oil (180 mg EPA and 120 mg DHA,
Banner Pharmacaps, Olds, AB, Canada) or placebo (olive oil).
Olive oil was selected as the placebo, as it was not expected to alter
plasma lipids or essential fatty acid metabolism (Thien et al, 1993;
Yaqoob et al, 2000). The fatty acid composition of the ﬁsh oil and
placebo capsules was determined using gas liquid chromatography
(Layne et al, 1996) (Table 1). All investigators and health care
workers were blinded to the treatment received throughout the
trial.
Subjects were instructed to take 18 capsules orally each day for
14 days. On day 0 and day 14 of supplementation, a non-fasting
sample of peripheral blood (16 mL) was drawn by a registered
nurse during in-home visits or in the clinic. Weight (without shoes
and wearing light clothes) was obtained at day 1 and day 14. On
day 1, height and pre-illness stable weight was also documented.
Patients were instructed by a research assistant to keep a 3-day
food day record during three consecutive days both at the begin-
ning and end of the 14 days supplementation period. The
nutrient content of coded food items was estimated using Food
Processor II nutrient analysis programme with the Canadian Nutri-
ent Data File (Esha Research, Salem, Oregon (Bruera et al, 1986).
The patients with advanced cancer were a cohort of subjects
participating in a larger study (Bruera et al, 2002). A random
sub-sample of 14 subjects per treatment arm were assigned to
receive more detailed measures of fatty acid status described here.
The number of patients entered into the study was based on the
ability to detect a change at a 5% signiﬁcance level in n-3 fatty
acids in plasma after 2 weeks of supplementation with ﬁsh oil.
The characteristics of the subjects are shown (Table 2).
Burn injury Patients and determinations are described elsewhere
in detail (Pratt et al, 2001). Ten adult patients were recruited who
had an age range from 20 to 65 years (mean=40+4 years). The
range of burn size was from 12–90% (mean=37+5% total body
surface area). A non-fasting venous blood sample (10 mL) was
collected within the ﬁrst 12 days (n=10) and after 50 days (n=8)
following the burn injury. Timepoints were compared using a
repeated measures ANOVA.
High dose chemotherapy with stem cell transplant Three
women, ages 35–47, with high risk stage II and III breast cancer
at the Cross Cancer Institute (Edmonton, Alberta), were treated
with high-dose chemotherapy with autologous stem cell transplant
(McCauley, 1996). Brieﬂy, patients underwent four 21 days cycles
of intravenously administered induction chemotherapy (5-ﬂuor-
ouracil, adriamycin and cyclophosphamide). Peripheral blood
stem cells were harvested on day 12 after the third induction
chemotherapy cycle. Approximately 3 weeks after the ﬁnal induc-
tion treatment, patients were admitted for administration of
intensive, high-dose chemotherapy (HDCT) consisting of cyclo-
phosphamide (6 g m
72), mitoxantrone (64 mg m
72) and
vinorelbine (95 mg m
72) over 4 days. After HDCT, they were
transplanted with autologous stem cells harvested earlier (Nabholtz
et al, 1997). Reconstitution was deﬁned to be clinically complete
when white blood cell counts returned to at least 2610
9 L
71
and platelet counts to at least 50610
9 L
71 (Ho et al, 1994). The
women did not have immunosuppressive or autoimmune disease,
or other types of cancer, and had a body mass index (BMI)
between 21–27. Blood (16 mL) was collected into heparinised
tubes at stem cell harvest (*2 weeks post induction chemotherapy)
and on the day of discharge (*2 weeks post-HDCT). A paired t-
test was used to compare pre- and post chemotherapy values.
Healthy subjects Blood was sampled from healthy subjects (n=6)
to serve as a reference for neutrophil and plasma PL composition.
The age range of healthy subjects was 21 to 59 years and all of the
subjects had BMI 525.
Isolation of plasma and neutrophils
Fatty acid composition was assessed on neutrophils isolated using
Ficoll Hypaque gradient centrifugation (Boyum, 1968). Plasma
was removed from the top of the gradient and frozen immediately
at 7708C. The neutrophil band was removed and cells washed
twice with Krebs-Ringer HEPES (KRH) buffer with BSA
(5 g L
71). Cells were cultured in complete culture media and cell
viability was assessed at greater than 99% for all samples. Cells
were pelleted and frozen immediately at 7708C until lipid analysis.
Fatty acid analysis of neutrophil and plasma PL
Neutrophil fatty acid composition A modiﬁed Folch method
was used to extract lipids from isolated neutrophils (Field et al,
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phosphatidylethanolamine (PE), phosphatidylinositol (PI), and
phosphatidylserine (PS)) fatty acid methyl esters was determined
using gas liquid chromatography as previously described (Pratt et
al, 2002). Peaks of fatty acid methyl esters were identiﬁed by
comparisons with standards purchased from Supelco (Bellefonte,
PA, USA) and Sigma Chemical (St. Louis, MO, USA). Per cent
of saturated (SFA), monounsaturated (MUFA), polyunsaturated
(PUFA), 20:4 n-6, total n-6 and n-3 fatty acids and n-6/n-3 ratios
are presented.
Plasma fatty acid PL Plasma PL fatty acid composition was
determined as previously described in detail (Pratt et al, 2001).
Brieﬂy, plasma (100 ml) fatty acids were extracted using chloro-
form/methanol and serum PL isolated on G-plates (Layne et al,
1996). For quantitative analysis, C17:0 standard was added to the
scraped serum PL (10 mg of C17:0) followed by direct methylation.
Fatty acid methyl esters separated by automated gas liquid chroma-
tography as described above. Total PL content of individual fatty
acids was calculated on both a quantitative and per cent
(w w
71) basis (Pratt et al, 2001).
Statistical analysis
Data are reported as mean+s.e.m. Variations in baseline and post-
supplementation fatty acid compositions of plasma and neutrophil
PL were analysed using BMI to stratify the subjects into high and
low groups (subjects with values above and below the overall group
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Table 1 Fatty Acid composition of the ﬁsh oil and olive oil
(Per cent Fatty acids)
Fatty acid Fish oil Olive oil (placebo)
C 14:0 6.9 0.1
C 16:0 14.8 19.6
C 16:1(7) 7.8 1.8
C 18:0 3.1 2.4
C 18:1(9) 8.9 60.3
C 18:1(7) 2.8 2.5
C 18:2(6) 1.3 12.3
C 18:3(3) 0.8 0.6
C 18:4(3) 2.8 nil
C 20:0 0.5 0.1
C2 0:1
a 2.0 0.2
C 20:2 (6) 0.2 nil
C 20:3(3) 1.0 nil
C 20:4(6) 0.8 nil
C 20:5(3) 17.8 0.1
C 22:0 0.1 0.1
C2 2:1
b 1.7 nil
C 22:4 (6) 0.4 nil
C 22:5(3) 2.4 nil
C 22:6(3) 12.8 0.1
C 24:1 0.6 nil
aIncludes 20:1(11), 20:1(9), 20:1(7)
bIncludes 22:1(11), 20:1(9), 20:1(7). Fatty
acid composition of ﬁsh oil and olive oil capsules was determined by gas liquid
chromatography.
Table 2 Characteristics of the advanced cancer patients
A. Subjects randomly allocated to ﬁsh oil supplementation
Patient Age Weight Cancer Mean number EPA/d DHA/d
ID (years) Gender (kg) site Metastasis capsules/d (mg kg bw) (mg kg bw)
01 48 M 73 pancreas no 16 38.5 25.7
02 65 M 87 prostate yes 17 35.4 23.6
03 61 F N/A lung no 8 33.6 22.4
04 73 M 54 rectum yes 8 25.0 16.7
05 58 M 68 rectum yes 17 45.4 30.3
06 67 M 92 prostate yes 12 23.5 15.7
07 82 M 63 jejunum yes 11 32.1 21.4
08 69 F 54 rectum yes 16 52.9 35.2
09 78 M 59 lung no 6 17.9 11.9
10 61 F 49 breast yes 6 30.3 20.2
11 77 F 62 adenocarcinoma yes 12 37.2 24.8
12 46 F 44 unknown yes 9 36.8 24.6
13 61 M 70 Cecum yes 16 41.4 27.6
mean+s.e.m. 65+36 5 +41 2 +1 34.6+2.6 23.1+1.7
B. Subjects randomly allocated to olive oil supplementation
Patient Age Weight Cancer Mean number
ID (years) Gender (kg) site Metastasis capsules per day
01 69 M 73 lung yes 10
02 63 M 73 kidney yes 18
03 77 M 45 parotid yes 8
04 81 M 67 prostate yes 14
05 59 M 54 leiomyosarcoma yes 6
06 73 M 58 lung no 9
07 66 M 50 stomach yes 15
08 62 M 55 rectum yes 6
09 76 M 60 colon yes 7
10 65 M 63 lung yes 7
mean+s.e.m. 69+26 0 +31 0 +1
Eligible participants were randomised using a computer-generated sequence to receive identical gelatin capsules containing ﬁsh oil or placebo (olive oil) for 14
days. The two treatment arms did not differ in age, weight, presence of metastasis or mean number of capsules per day.
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between the high and low groups. Speciﬁc correlations between BMI,
kcal kg
71 BW intake against plasma PL were performed. To measure
changes in fatty acid composition within a supplementation group,
a paired t-test was used. Differences between groups and time-
points were analysed using repeated measures ANOVA.
Signiﬁcant differences (P50.05) between treatments and day 0
and 14 were identiﬁed using least square means. All statistical
analyses were conducted using the SAS statistical package (Version
6.12, SAS Institute, Cary, NC, USA).
RESULTS
Subjects
Thirteen and 10 subjects completed 14 days of ﬁsh oil and place-
bo supplementation, respectively (Table 2) a total of 23 subjects.
Self-reported intakes of capsules did not differ signiﬁcantly
between treatments. Reasons for not completing the study
included failure to maintain intake of the oil capsules, complica-
tions due to cancer progression, and death (n=4). Groups did not
differ signiﬁcantly in age, body weight or the presence of metas-
tasis. The primary site of the cancer varied widely among
subjects in both groups (Table 2).
Baseline comparisons to reference groups
Plasma PL The baseline (pre-supplementation) levels and fatty
acid composition of plasma PL for the 23 advanced cancer patients
were contrasted with the other patient groups and healthy controls
(Table 3). Chemotherapy and burn patient groups were not
compared statistically to the advanced cancer patients because they
were not controlled cohorts for sex, age or body composition. The
most striking observation from this analysis was that total plasma
PL and most individual fatty acids in the PL of advanced cancer
patients, including the essential fatty acids, 18:2 n-6 and 18:3
n-3, were the lowest of all groups studied at *30% of the levels
observed in healthy subjects (Table 3). Of the long chain polyun-
saturated fatty acids (PUFA), only EPA levels were relatively
well-maintained (93% of healthy controls) in the advanced
cancer group. The ratio of mead acid (20:3 n-9) to 20:4 n-6, a
measure of essential fatty acid deﬁciencies (Spector, 2000), was
elevated in the advanced cancer patients (0.3+0.04) compared to
healthy subjects (mean=0.01+0.0). Twelve days after major burn
injury, levels of total plasma PL and most fatty acids therein were
intermediate between healthy subjects and patients with advanced
cancer and at 7 weeks postburn, plasma PL increased towards levels
seen in healthy controls (Pratt et al, 2001). The chemotherapy
group fell intermediate between the levels seen in healthy subjects
and the patients with advanced cancer for most fatty acids. The
most striking feature of the fatty acid proﬁles of the chemotherapy
patients was the very low levels of long chain (420 carbon long)
PUFA. After induction chemotherapy, all PUFA with 22 carbons
in chain length, with the exception of EPA and DHA, were below
the limit of detection (Table 3). After high dose chemotherapy,
DHA became undetectable and EPA levels fell to 0.1 mgm L
71 or
about 7% of control values. Fatty acids of the n-6 series (18:2
n-6 and 20:3 n-6) were also strikingly low after high dose
chemotherapy (22 and 41%, respectively, of healthy reference
values).
Neutrophil PL The fatty acid compositions of PC, PE, PI and PS
was determined on isolated neutrophils. Data is shown in Table 4
for PC, which comprises the largest proportion (*39%) of neutro-
C
l
i
n
i
c
a
l
Table 3 Plasma phospholipids by patient group
Breast Cancer
Burn Injury chemotherapy
Healthy 512 days post 450 days post After After high Advanced cancer
subjects burn injury burn injury Induction dose Pre-supplementation
(n=6) (n=10) (n=8) (n=3) (n=3) (n=23)
Fatty acid (mgm L
71 plasma)
C 16:0 207+31 135+7 160+14 74+15 53+86 4 +6
C 18:0 100+11 73+39 1 +12 52+16 32+63 9 +6
C 18:1(9) 70+10 62+35 0 +84 1 +92 9 +42 4 +3
C 18:2(6) 175+30 79+49 8 +14 73+23 38+75 1 +8
C 18:3 (3) 2+11 +0.2 2+11 +0.2 0.1+0.1 0.4+0.1
C 20:2(6) 2+0.4 1+0.3 2+0.2 3+11 +0.2 1+0.1
C 20:3(6) 17+31 5 +31 6 +31 4 +67 +31 +0.2
C 20:4(6) 68+11 31+44 6 +64 3 +14 35+92 5 +4
C 20:5(3) 2+0.4 2+0.3 2+11 +1 0.1+0.1 1+0.2
C 22:4(6) 2+0.3 1+0.2 1+0.2 nil
a nil
a 0.4+0.1
C 22:5(6) 2+0.4 1+0.1 1+0.4 nil
a nil
a 1+0.2
C 22:5(3) 4+13 +13 +1 nil
a nil
a 1+0.2
C 22:6(3) 21+31 0 +11 3 +31 +1 nil
a 9+2
S n-6 266+46 122+14 165+22 133+42 80+16 77+10
S n-3 29+41 5 +22 5 +33 +2 0.3+0.3 16+3
n-6/n-3 ratio 9+18 +19 +1 103+54 90+23 6+0.4
S PUFA 298+50 142+15 191+24 136+40 80+16 115+18
S SFA 321+42 212+19 281+30 126+31 85+13 117+13
S MUFA 101+17 78+88 1 +12 49+10 33+53 3 +4
Total 720+99 432+39 552+62 447+121 278+50 244+27
anil=50.04 mgm L
71. Phospholipids were isolated from plasma using thin layer chromatography and fatty acid composition was determined using gas
liquid chromatography. Fatty acids are expressed as mg mL-1 plasma and were calculated using 17:0 as the standard. Data are expressed as means+
s.e.m. Plasma PL were isolated from healthy subjects (n=6), in burn patients at two time points: within 12 days (n=10) and 450 days following burn
injury (n=8), in breast cancer patients at two time points: after induction chemotherapy (stem cell harvest, n=3) and after high dose chemotherapy
(discharge, n=3) and advanced cancer patients (n=23, Table 2): Groups were not statistically compared. Abbreviations: PUFA, polyunsaturated fatty
acids, MUFA, monounsaturated fatty acids, SFA, saturated fatty acids.
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in the signalling of the neutrophil oxidative burst (Cockcroft and
Stutchﬁeld, 1989; Hundt and Schmidt, 1992; Sayeed, 1998). Higher
levels of 20:4 n-6 in all PL classes of neutrophils (+80% in PI,
+80% in PC, +22% in PE and +100% in PS) contributed to greater
PUFA content and a higher n-6/n-3 fatty acid ratio in advanced
cancer patients compared to other patient groups and healthy
subjects (Table 4). This elevated PUFA content was matched with
lower saturated fatty acid content, primarily 16:0, whereas content
of monounsaturated fatty acids did not appear different than other
groups. Chemotherapy patients had undetectable levels of n-3 fatty
acids in neutrophil PI after induction chemotherapy and remained
so after HDCT.
Variation of fatty acid levels in patients with advanced
cancer
At baseline (pre-supplementation) patients with advanced cancer
appeared different than other patient groups in fatty acid composi-
tions of PL in plasma and neutrophils. There was also considerable
variation within the advanced cancer patient population for the
studied variables. We sought to explain some of this variation by
relating the compositions of plasma and cell PL to nutritional
status to interpret the data obtained here and to aid in the design
of future studies.
Measures of nutritional status BMI, total caloric intake, and fat
intake at the time of entry into the study were chosen as measures
of nutritional status. The mean percentage of calories derived from
fat was 31+7%. Caloric intake and total fat intake were highly
correlated (r=0.97, P=0.0001), therefore, caloric intake was used
in subsequent analysis. Both BMI and caloric intake varied over
a broad range and were not signiﬁcantly correlated (P=0.14).
The average BMI of the 23 subjects with advanced cancer was
20.7 kg m
72 with a range of 15 to 28 kg m
72, representing a
mixture of patients who would be regarded as severely under-
weight, underweight, within the normal range and even
overweight. Subjects were divided into two groups with BMI above
(high BMI) and below the overall group mean (low BMI; Figure
1). Caloric intake ranged from 488 to 2152 kcal day
71 with one
third (28%) of the subjects having intakes of 51000 kcal day
71.
Mean intakes did not differ signiﬁcantly between BMI groups
(low BMI=25+8 kcal kg
71 BW per day; high BMI=19+2
kcal kg
71 BW per day; Figure 1).
Fatty acids in plasma and neutrophil PL Although the average
levels of EPA and DHA in neutrophil membrane PL did not appear
different from other patient groups, the content of these fatty acids
were highly variable amongst patients with advanced cancer. Some
subjects had undetectable levels and others had up to 4% EPA or
DHA in either their PC or PI fractions. Total caloric intake did not
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Table 4 Fatty acid composition of phospholipid fractions of neutrophils compared to other patient groups
Breast Cancer
Burn Injury
a chemotherapy
Healthy 512 days post 450 days post After After high Advanced cancer
subjects burn injury burn injury Induction dose Pre-supplementation
(n=6) (n=10) (n=8) (n=3) (n=3) (n=23)
Fatty acid (Per cent w w
71) (Per cent w w
71)
Phosphatidylcholine
16:0 33+13 1 +23 1 +13 3 +13 1 +0.2 24+2
18:0 12+11 2 +11 2 +11 2 +11 3 +21 1 +1
18:1(9) 25+0.4 31+12 4 +22 8 +13 0 +12 8 +2
18:2(6) 10+19 +11 0 +21 5 +11 5 +11 4 +1
20:4(6) 8+13 +0.4 7+14 +14 +0.4 12+1
20:5(3) 2+11 +0.2 1+1 0.2+0.2 1+0.2 1+0.3
22:6(3) 0.3+0.2 0.4+0.1 1+0.1 nil
b 0.1+0.1 1+0.2
S n-6 21+11 4 +11 5 +22 2 +0.4 21+12 9 +2
S n-3 3+12 +0.3 3+0.4 0.4+0.2 1+12 +1
n-6/n-3 10.7+2.6 4.4+1.5 5+23 2 +71 9 +42 6 +4
S PUFA 24+11 7 +12 2 +12 2 +0.2 22+13 1 +2
S SFA 46+14 8 +14 8 +25 0 +0.4 47+13 7 +2
S MUFA 30+13 5 +12 8 +12 8 +13 2 +13 1 +1
Phosphatidylinositol
16:0 18+42 4 +31 7 +53 6 +32 6 +29 +2
18:0 25+52 8 +22 9 +21 6 +22 9 +0.3 26+5
18:1(9) 7+11 1 +17 +12 7 +32 5 +28 +2
18:2(6) 3+15 +14 +11 3 +18 +11 4 +3
20:4(6) 12+48 +11 8 +43 +11 2 +12 2 +4
20:5(3) 1+0.3 3+11 +1 nil
b nil
b 2+1
22:6(3) 1+0.2 0.2+0.1 1+0.3 nil
b nil
b 2+1
S n-6 25+51 7 +22 5 +31 7 +22 1 +14 0 +5
S n-3 3+0.2 3+14 +1 nil
b nil
b 5+1
n-6/n-3 11+3 5.8+1.4 11+3 N/A N/A 15+4
S PUFA 28+52 2 +22 9 +31 7 +22 1 +14 5 +5
S SFA 57+36 1 +15 9 +25 6 +45 4 +23 7 +6
S MUFA 13+11 7 +11 6 +22 7 +32 5 +21 4 +2
aPublished in part in Journal of Clinical Biochemistry and Nutrition (Pratt et al., 2002).
bnil=50.04%. N/A=Not applicable. Fatty acid composition of the
phosphatidylcholine and phosphatidylinositol fractions of neutrophils isolated from patient groups were determined by gas chromatography. Data are
expressed as means+s.e.m. Neutrophils were isolated from Plasma PL were isolated from healthy subjects (n=6), in burn patients at two time points:
within 12 days (n=10) and 450 days following burn injury (n=8), in breast cancer patients at two time points: after induction chemotherapy (stem cell
harvest) and after high dose chemotherapy (discharge) (n=3) and advanced cancer patients (Table 2; n=23). Groups were not statistically compared.
Abbreviations: PUFA, polyunsaturated fatty acids, MUFA, monounsaturated fatty acids, SFA, saturated fatty acids.
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advanced cancer had the highest levels of n-6 fatty acids in neutro-
phil PL (see Table 4) compared to all other subjects and this was
most marked in the patients with lower BMI. This was primarily
due to the low BMI group having signiﬁcantly greater 20:4 n-6
content in PC (16.0+2.0%) compared with the high BMI group
(9.7+2.3%; P=0.05) and for PI, where patients in the low BMI
group had twice the levels of 20:4 n-6 in PI (22.6+4.3%),
compared to the high BMI group (10.7+6.2%; P=0.05). BMI
and levels of 20:4 n-6 in neutrophil PI were inversely correlated
(r=70.61, P=0.02).
Neutrophils have been reported to lack delta-6-desaturase and
are dependent on incorporation of PUFA from plasma PL (Chil-
ton-Lopez et al, 1996; Barham et al, 2000), therefore, it would be
expected that cell and plasma PL PUFA levels would be related.
These relationships were strongest for total and individual n-3 fatty
acid levels. The total n-3 fatty acid content of neutrophil PC was
directly related to plasma PL n-3 fatty acid content (r=0.78;
P=0.001). By contrast, the 18:2 n-6 and 20:4 n-6 content of
neutrophil PL were not signiﬁcantly related to plasma PL levels
of these fatty acids. As would be expected based on the preceding
data, the n-6/n-3 ratio of plasma PL was directly related to the n-6/
n-3 ratio in neutrophil PC (r=0.67; P=0.007). The 20:3 n-9/20:4
n-6 ratio in plasma PL of advanced cancer patients did not differ
between the high and low BMI groups (mean=0.3+0.04).
Effects of ﬁsh oil and olive oil supplementation
Fatty acid composition of plasma PL Subjects consuming olive
oil for 2 weeks did not exhibit signiﬁcant changes in plasma PL
fatty acid composition compared with pre-supplementation values
(data not shown). Neither the ﬁsh oil nor placebo group demon-
strated signiﬁcant increases in plasma total PL concentrations
over the 2-week supplementation period (not shown). After
supplementation with ﬁsh oil, there was a signiﬁcant increase in
the fraction of EPA (+2–34 mgm l
71) and DHA (+2–
14 mgm l
71) in plasma PL (Table 5). Fish oil supplementation also
resulted in a 15% reduction in 18:2 n-6 but did not change the
20:4 n-6 content of plasma (Table 5). After 14 days, the ratio of
20:3 n-9/20:4 n-6 was signiﬁcantly different between ﬁsh oil
and placebo groups (0.18+0.01 vs 0.27+0.04; P=0.03). The
change in body weight gain during the 2 week supplementation
period was directly related to the increase in EPA content in plas-
ma PL (r=0.86; P=0.006; Figure 2).
Fatty acid composition of neutrophil PL The fatty acid compo-
sition of neutrophil PL classes was not affected by olive oil
supplementation (data not shown) and largely unaffected by ﬁsh
oil supplementation. It is of note that in spite of a large elevation
of plasma levels of EPA with ﬁsh oil treatment (Table 5), there was
no parallel change in the EPA and DHA content of neutrophil
membranes, nor in the amount of total n-3 fatty acids (Table 5).
The only signiﬁcant effect of ﬁsh oil supplementation on neutro-
phil PL fatty acid composition was a reduction in 20:4 n-6
content in the PI fraction (Table 5) to levels similar to control
subjects. In PC, PE and PS there was a partial reduction of 20:4
n-6 levels, but this was not statistically signiﬁcant.
DISCUSSION
We made a comprehensive assessment of plasma and neutrophil
PL fatty acids in a mixed group of advanced cancer patients experi-
encing weight loss. We observed very low levels of plasma total PL
and unusual fatty acid content of neutrophil membrane PL that
was marked by elevated levels of 20:4 n-6. Oral supplementation
with ﬁsh oil for 2 weeks caused a signiﬁcant increase in plasma
PL levels of EPA and DHA, but did not alter total PL concentra-
tion in plasma nor did it raise n-3 fatty acid content in
neutrophil PL. These results suggest multiple alterations in metabo-
lism of lipids and speciﬁc fatty acids in cancer patients. While the
causes of fatty acid abnormalities in advanced cancer have not been
clearly characterised, the ﬁndings in this preliminary study in a
small group of advanced cancer patients advance current under-
standing by outlining relationships linking fatty acid status and
weight loss, as well as identifying potential causes of altered fatty
acid proﬁles and obstacles that may impede lipid supplementation.
There is very little available data on the fatty acid status of
patients with advanced cancer. Our context for comparison
included healthy adults as well as additional patient groups from
the same local population who had major burn injury (inﬂamma-
tory injury; Tredget and Yu, 1992; Foex and Shelly, 1996) or were
undergoing chemotherapy. The results presented here represent an
initial approach and it is necessary to employ caution in comparing
the data obtained for cancer patients with the other patient groups
which serve mainly to place the advanced cancer patients in a
context for discussion. Within the limitations of these compari-
sons, a number of points merit attention. Firstly, patients with
advanced cancer had very low levels of plasma PL. Other studies
on lipid supplementation reported the fraction of n-3 fatty acids
in plasma PL, but not the plasma PL levels (Wigmore et al,
1996, 1997; Barber et al, 1999), so this abnormality was previously
undetected. The cause(s) or the point in time that low levels of
plasma PL evolved has not been identiﬁed, therefore it would seem
important to follow this variable in newly diagnosed patients over
the disease trajectory in further studies. Our data suggests
chemotherapy as one possible cause for low levels of plasma PL.
The inﬂammatory response, reported to occur in advanced cancer
(Tisdale, 1999), may also contribute to reduced levels of plasma PL
as patients with major burn injury had low plasma PL (Pratt et al,
2001) although to a lesser extent than the advanced cancer patients.
High density lipoproteins (HDL) and low density lipoproteins
(LDL), which account for the majority of total PL in plasma, have
been recently reported to be reduced in a large, mixed group of
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Figure 1 Advanced cancer patients were stratiﬁed at baseline into high
and low BMI groups based on the group mean (20.7 kg m
72; n=23). Sub-
jects with BMIs above the group mean represent the low BMI group
(n=12) and subjects with BMIs above the group mean comprise the high
BMI group (n=11). Columns represent mean+s.e.m. of the high and low
BMI groups. The range of mean caloric intakes (days 1, 2 and 3 of supple-
mentation) within each BMI grouping are shown for each patient using data
points. Caloric intakes were estimated using 3 day food records and ana-
lysed using the Food Processor II Nutrient Analysis Program with the
Canadian Nutrient Data File. Signiﬁcant differences (P50.05) between
BMI groupings and corresponding caloric intakes were detected using a
t-test.
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2000), and these may account in part for the low levels of total
PL observed here. Both HDL and LDL levels would be affected
by a proximal deﬁcit in lipid absorption or of chylomicron or
VLDL synthesis, and studies of lipid incorporation in advanced
cancer patients would appear warranted.
A second unusual observation was high n-6/n-3 fatty acid ratios
in plasma and cell PL of patients with advanced cancer, with an
especially high fraction of 20:4 n-6 in all PL classes of neutrophils.
It is not clear whether altered diet or altered metabolism of fatty
acids would account for these differences, nor is it known to what
extent the disease and therapy might have contributed. Subjects
with the lowest BMIs exhibited higher levels of n-6 fatty acids in
neutrophil PL and higher n-6/n-3 ratios in both plasma and
neutrophil PL. This observation is consistent with the rationale
given for n-3 fatty acid supplementation; i.e. that n-6 fatty acids
are permissive for the action of catabolic mediators (Barber,
2001). However, while high levels of n-6 fatty acids were associated
with BMI, it is not clear whether this was a cause or a consequence
of the wasting process. BMI is commonly used to stratify patients
in trials of anorexia/cachexia (Bruera et al, 1999; Loprinzi et al,
1999). The ratios of n-6/n-3 fatty acids may also be a useful criter-
ion for stratiﬁcation for future trials of ﬁsh oil supplementation.
Our data suggests chemotherapy as one possible cause for altered
fatty acid composition, especially depletion of PUFA. Although
preliminary, the most striking feature of the fatty acid proﬁles of
the chemotherapy patients was the very low levels of long chain
PUFA (both n-6 and n-3 fatty acids) in plasma and cell PL. The
n-6/n-3 ratios were considerably skewed by chemotherapy treat-
ments, with the polyunsaturated n-3 fatty acids being most
strongly affected. These changes were observed after induction
chemotherapy and exhibited further declines after a high dose
chemotherapy regimen, both of which employed widely used
agents. Cytotoxic agents have been reported to interfere with the
metabolism of PUFA (Marra et al, 1986) and may limit the endo-
genous production of EPA and DHA from 18:3 n-3 and of 20:4
n-6 from 18:2 n-6. This may support an argument to attempt to
increase PUFA levels prior to chemotherapy or to include supple-
mentation with post-chemotherapy re-alimentation.
We selected 14 days of supplementation, as this length of time
was thought to support a high compliance and low drop out rate
in a relatively fragile patient group. The efﬁcacy of fatty acid incor-
poration during our short- term ﬁsh oil supplementation may be
compared with related studies. Other authors employing ﬁsh oil
capsules (Barber et al, 1998; Gogos et al, 1998) or ﬁsh oil –
enriched enteral formula (Barber, 2001) to deliver similar amounts
of ﬁsh oil to those reported here, report comparable elevations of
per cent n-3 fatty acids in plasma PL of advanced cancer patients
using longer intervention periods (Wigmore et al, 1997; Barber et
al, 1999). In the present study, the ratio of 20:3 n-9 to 20:4 n-
6 in plasma PL was reduced following the ﬁsh oil treatment and
may suggest an improvement in essential fatty acid status. All
patients allocated to receive ﬁsh oil exhibited increased levels of
EPA and DHA in plasma PL, however, we observed poor corre-
spondence between the intake of capsules reported by our
patients and the magnitude of alterations in EPA and DHA in their
plasma PL. It is unlikely that this discrepancy can be explained
entirely by inaccurate reporting of capsules ingested. It is more
likely that heterogeneity exists amongst patients in fatty acid diges-
tion, absorption and incorporation into plasma PL. Given the
heterogeneity of the individual patient response of plasma PL
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Figure 2 Data points represent the change in body weight from day 1 to
day 14 of ﬁsh oil supplementation and the change in plasma EPA for sub-
jects in the ﬁsh oil group (n=9). Body weight at either days 1 or 14 was not
available for the four subjects missing in the analysis. There was a signiﬁcant
positive relationship between change in body weight and the change in
plasma EPA.
Table 5 Effects of ﬁsh oil supplementation before and after 14 days in plasma and neutrophil PL
Plasma PL Neutrophil PC Neutrophil PI
Pre-FO Post FO Pre-FO Post FO Pre-FO Post FO
Fatty acid (Per cent fatty acids) (Per cent fatty acids) (Per cent fatty acids)
16:0 27.6+1.0 27.7+1.1 26.0+2.5 24.0+1.4 9.7+3.3 14.2+2.9
18:0 13.9+0.5 14.9+0.8 11.9+0.7 13.2+1.1 28.0+7.2 25.0+4.0
18:1n-9 10.9+1.0 10.3+0.5 25.8+1.9 30.5+2.0 7.3+2.6 14.3+3.0
18:2n-6 19.9+0.9
a 16.6+1.1
b 15.2+2.5 11.1+1.1 12.1+4.6 7.1+1.4
20:4n-6 10.2+0.7 9.2+0.8 14.1+2.3 11.9+2.6 26.8+5.9
a 12.5+2.6
b
20:5n-3 0.7+0.1
a 4.4+0.7
b 0.2+0.1 0.1+0.1 2.1+1.5 1.6+0.8
22:6n-3 4.1+0.6
a 5.8+0.8
b 0.7+0.3 0.8+0.4 1.4+0.7 4.1+1.9
S n-6 31.5+1.4 28.3+1.7 31.9+2.8 24.8+2.7 39.8+3.8 24.6+3.9
S n-3 6.2+0.6
a 11.8+1.4
b 1.6+1.0 1.6+0.8 3.5+0.5 8.3+3.4
S PUFA 40.5+1.9 41.2+2.1 33.6+3.2 26.4+3.1 44.5+3.8
a 32.9+4.6
b
S SFA 45.4+2.0 47.0+1.2 39.7+3.1 39.1+1.9 37.1+2.0 46.4+4.7
S MUFA 14.2+2.0 14.2+0.5 28.7+1.6 33.6+2.2 13.7+1.6
a 20.8+2.5
b
Fatty acid composition of plasma PL and the PC and PI fractions of neutrophil PL (separated by thin layer chromatography) isolated before and after 14
days of PUFA supplementation, was determined by gas chromatography analysis and is expressed a percent of total fatty acids. Data are expressed as
means+s.e.m. (n=13). Signiﬁcant differences between groups were determined using an ANOVA and differences identiﬁed using least square means.
Values within a PL grouping not sharing common superscripts are signiﬁcantly (P50.05) different.
a,bWithin a column grouping (i.e. pre vs post FO) are
signiﬁcantly different.
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2002) did not detect a signiﬁcant treatment effect on weight or
body composition. However, in this smaller subgroup of patients,
the magnitude of the change in plasma PL EPA, was signiﬁcantly
related to the amount of weight gained by the subjects receiving
ﬁsh oil, providing evidence for a dose response relationship. These
results underline the importance of plasma PL fatty acid levels as a
primary measure in oil supplementation studies.
Feeding ﬁsh oil to cancer patients for a short period can alter
the fatty acid composition of peripheral immune cells. Supplemen-
tation did not raise n-3 fatty acid levels, however we did observe
signiﬁcant reductions in 20:4 n-6 in the PI fraction of neutrophils.
PI is linked to a major receptor binding site (Hundt and Schmidt,
1992) important in intracellular signalling and activation (Tissot et
al, 1991). Increasing the n-3 fatty acid composition of PI has been
reported to be one mechanism for attenuation of pro-inﬂamma-
tory responses (Sperling et al, 1993). Elevations in n-3 fatty acids
accompanied by reductions in 20:4 n-6, in the PC and PE frac-
tions of neutrophils has been reported after 3 weeks of ﬁsh oil
supplementation in healthy volunteers consuming larger daily
doses of ﬁsh oil (9.4 g EPA and 5 g DHA; Sperling et al, 1993).
It is unclear why we did not see any increase in EPA or DHA in
neutrophil PL, in spite of signiﬁcantly increased levels of n-3 fatty
acids in plasma, as changes have been observed within 14 days in
healthy subjects (Lee et al, 1985; Tiwary et al, 1987; Chapkin and
Carmichael, 1990; Sperling et al, 1993). The low concentrations
of plasma PL may have limited the availability and subsequent
incorporation of these fatty acids into cell membranes (Chapkin
et al, 1988) or supplemented fatty acids may have been directed
to oxidative pathways (Korber et al, 1999; Zuijdgeest-van Leeuwan
et al, 2000) rather than incorporated into cellular membranes. The
capacity to impact on immune functions by altering membrane
ﬂuidity, enzyme activities and intracellular signals (Traill and Wick,
1986; Sakata et al, 1987; Graber et al, 1994; Peck, 1994b; de Pablo
and Alvarez de Cienfuegos, 2000) through nutritional supplemen-
tation is assumed to be dependent on incorporation of
supplemented fatty acids into membranes (Russell et al, 1987;
Kinsella, 1990; Lester, 1990; Peck, 1994a) and the optimal condi-
tions of supplementation for this to occur are presently
unknown. Therefore, obstacles exist that must be addressed in
future trials aiming to alter immune functions through lipid
supplementation.
At whatever time fatty acid supplementation may be contem-
plated, there are important issues pertaining to dose and
delivery. Provision of high doses of ﬁsh oil and puriﬁed EPA
may be limited by untoward gastrointestinal side effects, which,
in some cases, may be managed by dose reduction or pancreatic
enzyme supplements (Barber, 2001). Other limiting factors may
include pancreatic secretions, absorption of fatty acids, biosynthesis
of chylomicron lipid and apoproteins in enterocytes, hepatic
uptake of chylomicron remnants and formation of lipid and
apoproteins of VLDL, lipoprotein metabolism in blood and trans-
fer of lipid constituents to cells. It would seem critical to determine
what impediment(s) exist to propose timely and effective nutri-
tional supplementation. Assessment of fatty acid status and lipid
metabolism from the time of diagnosis and throughout the
progression of different tumour types and characteristic therapies
will provide valuable information regarding the timing of supple-
mentation. Further studies investigating the metabolism of n-3
fatty acids in advanced cancer patients are warranted.
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